Unknown

Dataset Information

0

Multi-tiered approach to detect autoimmune cross-reactivity of therapeutic T cell receptors.


ABSTRACT: T cell receptor (TCR)-engineered T cell therapy using high-affinity TCRs is a promising treatment modality for cancer. Discovery of high-affinity TCRs especially against self-antigens can require approaches that circumvent central tolerance, which may increase the risk of cross-reactivity. Despite the potential for toxicity, no standardized approach to screen cross-reactivity has been established in the context of preclinical safety evaluation. Here, we describe a practical framework to prospectively detect clinically prohibitive cross-reactivity of therapeutic TCR candidates. Cross-reactivity screening consisted of multifaceted series of assays including assessment of p-MHC tetramer binding, cell line recognition, and reactivity against candidate peptide libraries. Peptide libraries were generated using conventional contact residue motif-guided search, amino acid substitution matrix-based search unguided by motif information, and combinatorial peptide library scan-guided search. We demonstrate the additive nature of a layered approach, which efficiently identifies unsafe cross-reactivity including one undetected by conventional motif-guided search. These findings have important implications for the safe development of TCR-based therapies.

SUBMITTER: Ishii K 

PROVIDER: S-EPMC10371023 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Multi-tiered approach to detect autoimmune cross-reactivity of therapeutic T cell receptors.

Ishii Kazusa K   Davies John S JS   Sinkoe Andrew L AL   Nguyen Kilyna A KA   Norberg Scott M SM   McIntosh Crystal P CP   Kadakia Tejas T   Serna Carylinda C   Rae Zachary Z   Kelly Michael C MC   Hinrichs Christian S CS  

Science advances 20230726 30


T cell receptor (TCR)-engineered T cell therapy using high-affinity TCRs is a promising treatment modality for cancer. Discovery of high-affinity TCRs especially against self-antigens can require approaches that circumvent central tolerance, which may increase the risk of cross-reactivity. Despite the potential for toxicity, no standardized approach to screen cross-reactivity has been established in the context of preclinical safety evaluation. Here, we describe a practical framework to prospect  ...[more]

Similar Datasets

| S-EPMC7642207 | biostudies-literature
| S-EPMC5307354 | biostudies-literature
| S-EPMC4887163 | biostudies-literature
| S-EPMC11381414 | biostudies-literature
| S-EPMC11110530 | biostudies-literature
| S-EPMC6645400 | biostudies-literature
| S-EPMC10478470 | biostudies-literature
| S-EPMC10724690 | biostudies-literature
| S-EPMC3164330 | biostudies-literature
| S-EPMC6508580 | biostudies-literature